According to the new market research report "Pulmonary Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Forecasts to 2021", published by MarketsandMarketsâ„¢,The global pulmonary drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period.
Donâ€™t miss out on business opportunities in Pulmonary Drug Delivery Market. Speak to our analyst and gain crucial industry insights that will help your business grow:
Growth in this market is mainly driven by increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis. Emerging markets such as India, China, & Japan and growth in online marketing channels are expected to offer lucrative growth opportunities for market players in the coming years. On the other hand, factors such as regulatory issues and pricing pressures are the major factors restraining market growth.
The pulmonary drug delivery market is segmented based on formulations, canister type, applications, end users, and regions. On the basis of end user, the market is segmented into hospitals & clinics and homecare settings. The hospitals & clinics segment dominated the market in 2016, this is attributed to the increasing incidence of diseases such as pneumonia and acute exacerbation of COPD (AECOPD) is driving the number of hospitalizations each year.
BrowseÂ and in-depth TOC on "Biopsy Devices Market "
104 - Tables
33 - Figures
150 - Pages
View more detailed TOC @
Based on canister type, the market is segmented into plain and coated canister. The coated canister segment is expected to be the fastest growing market in canister type segments in the market during the forecast period. This is attributed to advantages such as robust profile for filling, avoiding crimping, and withstanding the pressure associated with the type of propellant (HFAs or CFCs).
Currently, North America dominates the pulmonary drug delivery market, and Asia represents the second-largest regional market.Â North America is further classified as U.S. and Canada.
The U.S. is expected to account for the largest share of the North American pulmonary drug delivery market in 2016. The large share of this market can be attributed to factors such as growing prevalence of lung and respiratory diseases, technological developments, and the presence of various players focusing on the development of digital inhalers in the country.
Get Free Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=179682410
Moreover, the Asian market is expected to register the highest CAGR during the forecast period due to the rapidly growing geriatric population, growing adoption of an unhealthy lifestyle, growing urbanization, exposure to smoke & chemicals, and the subsequent increase in the prevalence of COPD in the region. Asia is further classified into Japan,India, and China, Japan is expected to account for theÂ largest share of the Asian pulmonary drug delivery market in 2016. This largest share is attributed to favorable healthcare reimbursement scenarios and insurance coverage. Insurance coverage is mandated by the government and regulated under the Universal Health Insurance System
Prominent players in the pulmonary drug delivery market include Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline (U.K.), Boehringer Ingelheim GmbH (Germany), 3M (U.S.), AstraZeneca plc (U.K.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Omron Corporation (Japan), and Sunovion Pharmaceuticals Inc. (U.S.).
MarketsandMarketsÂ™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companiesÂ’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarketsÂ™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarketsÂ™ are tracking global high growth markets following the "Growth Engagement Model Â– GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarketsÂ™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarketsÂ™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarketsÂ’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
Pulmonary Drug Delivery Market worth 52.37 Billion USD by 2021
Contact Name: 1marketsandmarkets
Contact Email: email@example.com
Contact Email: firstname.lastname@example.org